Interleukin-22 Ameliorates Cerulein-Induced Pancreatitis in Mice by Inhibiting the Autophagic Pathway by Feng, Dechun et al.





I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2012; 8(2):249-257.  doi: 10.7150/ijbs.3967 
Research Paper 
Interleukin-22 Ameliorates Cerulein-Induced Pancreatitis in Mice by In-
hibiting the Autophagic Pathway   
Dechun Feng1#, Ogyi Park1#, Svetlana Radaeva2, Hua Wang1, Shi Yin1, Xiaoni Kong1, Mingquan Zheng3, 
Sam Zakhari2, Jay K. Kolls3, Bin Gao1  
1.  Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD 20892, USA; 
2.  Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD 20892, USA;  
3.  Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. 
# DF and OP contributed equally to this work. 
  Corresponding  author:  Bin  Gao,  M.D.,  Ph.D.,  NIAAA/NIH,  5625  Fishers  Lane,  Bethesda,  MD  20892.  E-mail: 
bgao@mail.nih.gov. This work was supported by the intramural program of NIAAA, NIH.  
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.12.16; Accepted: 2012.01.01; Published: 2012.01.06 
Abstract 
Pancreatitis occurs when digestive enzymes are activated in the pancreas. Severe pancreatitis 
has a 10-30% mortality rate. No specific treatments for pancreatitis exist now. Here, we 
discovered that interleukin-22 (IL-22) may have therapeutic potential in treating acute and 
chronic pancreatitis. Wild-type and IL-22 knockout mice were equally susceptible to ceru-
lein-induced acute and chronic pancreatitis, whereas liver-specific IL-22 transgenic mice were 
completely resistant to cerulein-induced elevation of serum digestive enzymes, pancreatic 
necrosis and apoptosis, and inflammatory cell infiltration. Treatment of wild-type mice with 
recombinant IL-22 or adenovirus IL-22 markedly attenuated the severity of cerulein-induced 
acute and chronic pancreatitis. Mechanistically, we show that the protective effect of IL-22 on 
pancreatitis was mediated via the induction of Bcl-2 and Bcl-XL, which bind to Beclin-1 and 
subsequently inhibit autophagosome formation to ameliorate pancreatitis. In conclusion, IL-22 
ameliorates cerulein-induced pancreatitis by inhibiting the autophagic pathway. IL-22 could be 
a promising therapeutic drug to treat pancreatitis. 
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Introduction 
Pancreatitis is inflammation of the pancreas that 
can occur in acute or chronic forms [1, 2]. Acute pan-
creatitis is marked by the sudden onset of right upper 
quadrant or epigastric pain, whereas chronic pancre-
atitis is characterized by a recurring or persistent ab-
dominal pain with or without steatorrhea or diabetes 
mellitus [1, 2]. Alcohol consumption is a leading cause 
for both acute and chronic pancreatitis, followed by 
gallstones and autoimmune diseases etc [1-3]. Many 
alcoholic  patients  develop  chronic  pancreatitis  soon 
after surviving a second attack of acute pancreatitis [3, 
4]. Mild pancreatitis is usually self-limited, with less 
than 5% mortality, whereas severe acute pancreatitis 
is associated with 10-30% mortality [5, 6]. The current 
treatment for pancreatitis is supportive and consists of 
fluid and salt replacement and pain management. No 
specific treatments are available at this time [1, 2]. It is 
generally believed that pancreatitis is caused by the 
self-digestion of pancreatic acinar cells following the 
conversion  of the inactive trypsinogen to the active 
trypsin [1, 2, 7]. However, the mechanisms underlying 
the pathogenesis of pancreatitis are not fully under-
stood.  
Interleukin-22 (IL-22), a recently identified type 
II cytokine that belongs to the IL-10 family [8], can be 
produced by many types of cells, including Th17, T, 
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NK, and NKT cells, but it only targets epithelial cells 
due to the restricted expression of IL-22R1 on these 
cells [9-11]. Through binding to IL-22R1 on various 
types  of  epithelial  cells,  including  hepatocytes  and 
intestinal  epithelial  cells,  IL-22  has  been  shown  to 
protect  against  concanavalin  A-induced  hepatitis 
[12-14], inflammatory bowel disease [15], and ulcera-
tive colitis [16]. Similarly, acinar cells, the pancreatic 
epithelial  cells,  also  express  high  levels  of  IL-22R1 
[17]. However, the functions of IL-22 in acinar cells 
remain  largely  unknown.  Because  IL-22  is  a 
well-documented survival factor for hepatocytes and 
liver  cancer  cells  [12,  14,  18],  we  hypothesize  that 
IL-22 may also protect against acinar cell death and 
pancreatitis. In this paper, we tested this hypothesis in 
a  model  of  pancreatitis  induced  by  the  injection  of 
cerulein. Our results reveal that IL-22 treatment ame-
liorates  cerulein-induced  pancreatitis  by  inhibiting 
autophagy, suggesting that IL-22 may have therapeu-
tic potential for the treatment of pancreatitis.  
Materials and Methods 
Materials 
 Anti-STAT3,  anti-phospho-STAT3,  anti-Bcl-2, 
anti-LC3,  anti-USP9x,  anti-Bcl-XL,  and  anti-Beclin-1 
antibodies were obtained  from Cell Signaling Tech-
nology (Danvers, MA). Anti-Mcl-1 antibody (Abcam, 
Cambridge,  MA),  anti-VMP1  antibody  (Enzo  Life 
Sciences, Farmingdale, NY), and anti-MPO antibody 
(Biocare Medical, Concord, CA) were also purchased. 
IL-22  ELISA  kit  was  obtained  from  R&D  Systems 
(Minneapolis, MN).  
Mice 
Liver-specific  IL-22  transgenic  mice  in  a 
C57BL/6  background  were  generated  as  described 
previously [14]. The IL-22TG heterozygous male mice 
were bred with female C57BL/6 mice, producing ap-
proximately 50% IL-22TG heterozygous mice and 50% 
WT littermate controls. All animal experiments were 
approved by the NIAAA animal care and use com-
mittee.  IL-22  knockout  (KO)  mice  on  a  C57BL/6 
background  were  kindly  provided  by  Dr.  Wenjun 
Ouyang (Genentech, San Francisco, California).  
Histological analysis and immunohistochem-
istry 
Formalin-fixed  pancreas  samples  were  pro-
cessed, and 4-m thick paraffin sections were stained 
with  hematoxylin  and  eosin  (H&E)  for  histological 
analysis.  To  detect  apoptotic  cells,  the  terminal  de-
oxynucleotidyl  transferase  dUTP  nick  end  labeling 
(TUNEL)  assay  was  performed  using  a  kit  from 
Milipore (Temecula, CA). To detect myeloperoxidase 
(MPO)  and  Microtubule-associated  protein  1A/1B- 
light chain 3 (LC3), pancreas sections were incubated 
with  primary  antibodies  after  antigen  retrieval  and 
visualized by DAB.  
Administration of mice with IL-22 adenovirus 
IL-22 adenovirus and control adenovirus-empty 
vectors were made as described previously [14]. Mice 
were  injected  intravenously  (i.v.)  with  adenovi-
rus-IL-22  (5×108  pfu)  or  adenovirus-empty  vector 
(5×108 pfu)  
Experimental pancreatitis 
Acute  pancreatitis  was  induced  by  hourly  in-
traperitoneal  (i.p.)  injections  of  50  μg/kg  cerulein 
(Sigma) for 7 times as described [19]. Mice were sacri-
ficed 7 hours after the first cerulein injection. For ex-
ogenous  recombinant  IL-22  treatment,  recombinant 
IL-22 (1 g/g) (Genescript, Piscataway, NJ) was ad-
ministered (i.p) to mice 2 hours before the first ceru-
lein injection. Chronic pancreatitis was induced by 7 
hourly  injections  (i.p)  of  50  μg/kg  cerulein  once  a 
week for 4 weeks. Mice received adenovirus-IL-22 or 
adenovirus-empty vector during the third week.  
Blood chemistry 
Serum  amylase  and  lipase  levels  were  deter-
mined using the IDEXX analyzer system (IDEXX La-
boratories, Westbrook, ME).  
Western blot and immunoprecipitation 
 Western  blots  were  performed  as  described 
previously  [20].  For  immunoprecipitation,  protein 
was extracted from the pancreas of WT or IL-22TG 
mice  and  incubated  with  Bcl-2  or  Bcl-XL  antibodies 
overnight. Protein G beads were then added and in-
cubated  for  4  hours.  Immunoprecipitates  were  ana-
lyzed by Western blot. 
Electron microscope (EM) 
One-mm3 pancreatic tissue samples were fixed 
with  2.5%  glutaraldehyde  in  0.15  M  sodium  caco-
dylate (pH 7.4) overnight, postfixed with 1% OsO4, 
stained en bloc with 1.5% uranyl acetate, dehydrated 
in ethanol, and embedded in epoxy resin. Ultrathin 
sections were stained with uranyl acetate and Reyn-
old's  lead  citrate  and  examined  with  a  Hitachi-600 
electron microscope. 
Statistical analysis 
Data are expressed as the mean  SD. To com-
pare  values  obtained  from  three  or  more  groups, 
one-factor analysis of variance (ANOVA) was used, 




obtained  from  two  groups,  the  Student’s  t-test  was 
performed. Statistical significance was assumed at the 
P<0.05 level. 
Results  
IL-22TG mice are resistant to cerulein-induced 
acute and chronic pancreatitis 
To determine the effects of IL-22 on pancreatitis, 
we compared cerulein-induced acute pancreatitis in 
WT,  IL-22KO,  and  IL-22TG  mice.  As  illustrated  in 
Figure  1A,  without  cerulein  treatment  (phosphate 
buffered saline [PBS] -treated groups), pancreas ap-
pearance and weight and serum amylase and lipase 
levels  were  similar  between  the  WT,  IL-22KO,  and 
IL-22TG mice. Repeated injection of cerulein, which is 
a  decapeptide  analog  of  cholecystokinin,  increased 
the pancreas and body weight ratio and serum amyl-
ase and lipase levels in the WT and IL-22KO mice, but 
not  in  the  IL-22TG  mice.  In  addition,  as  shown  in 
Figure  1A,  serum  IL-22  levels  were  undetectable  in 
the PBS-treated WT and IL-22KO mice but were de-
tected at high levels in the IL-22TG mice. Repeated 
injection of cerulein did not elevate serum IL-22 levels 
in the WT or IL-22KO mice, nor did it affect serum 
IL-22 levels in the IL-22TG mice.  
The histological analyses shown in Figure 1B in-
dicate  significant  tissue  necrosis  in  the  ceru-
lein-treated  WT  and  IL-22KO  mice,  but  not  in  the 
IL-22TG  mice.  The  numbers  of  TUNEL+  apoptotic 
acinar cells and MPO+ neutrophils were elevated in 
the  WT  and  IL-22KO  mice  after  cerulein  treatment, 
whereas  this  elevation  was  barely  detectable  in  the 
cerulein-treated IL-22TG mice (Fig. 1B).  
 
 
Figure 1. IL-22TG mice are resistant to cerulein-induced acute pancreatitis. WT, IL-22KO, and IL-22TG mice were treated 
seven times with cerulein or PBS injections to induce acute pancreatitis. Mice were sacrificed one hour after the last injection. The ratio 
of the pancreas/body weight, serum levels of IL-22, and amylase and lipase levels were measured (A). Representative H&E staining, TUNEL 
staining, and MPO staining are shown in the left panel of (B). The pathology score and the number of TUNEL+ and MPO+ cells are 
summarized in the right panel of (B). *** P < 0.001 compared to cerulein-treated WT mice. Data are representative of three different 





Figure 2. IL-22TG mice are resistant to cerulein-induced chronic pancreatitis. WT and IL-22TG mice received seven cerulein 
or PBS injections weekly for four weeks to induce chronic pancreatitis. Mice were sacrificed one hour after the last injection. Repre-
sentative H&E staining, TUNEL staining, and MPO staining are shown (A). Serum levels of amylase and lipase were measured. The pa-
thology score and the number of TUNEL+ and MPO+ cells are summarized (B). ***P<0.001 compared to cerulein-treated WT mice. Data 
are representative of three different experiments, 5~7 mice in each group. 
 
We also tested the severity of cerulein-induced 
chronic pancreatitis (4-week treatment) in the WT and 
IL-22TG  mice.  As  illustrated  in  Figure  2A,  4-week 
repeated  cerulein  treatment  markedly  induced 
chronic pancreatitis, as evidenced by an elevation in 
serum  amylase  and  lipase  levels  and  of  pancreatic 
necrosis, TUNEL+ cells, and MPO+ neutrophils in the 
pancreases of the WT mice. In contrast, such repeated 
cerulein treatment induced only mild pancreatitis in 
the IL-22TG mice (Fig. 2A and 2B).  
Treatment with recombinant mouse IL-22 
(rmIL-22) or adeno-IL-22 protects mice from 
cerulein-induced acute and chronic pancreati-
tis  
To evaluate the therapeutic potential of IL-22 in 
acute  pancreatitis,  we  injected  mice  with  rmIL-22 
protein two hours before the first cerulein injection. 
As illustrated in Fig. 3A, pretreatment with rmIL-22 
did not affect cerulein-mediated increase in the pan-
creas/body  weight  ratio,  but  markedly  diminished 
the  elevation  of  serum  amylase  and  lipase  levels. 
Consistently,  cerulein-induced  tissue  damage  and 
inflammatory cell infiltration were also greatly ame-
liorated by rmIL-22 treatment, as indicated by H&E 
staining and MPO staining (Fig. 3B).  
The therapeutic efficacy of IL-22 was also tested 
in  a  cerulein-induced  chronic  pancreatitis  model. 
Mice were repeatedly injected seven times with ceru-
lein once a week for four weeks and received adeno-
virus-IL-22  (Ad-IL-22)  or  adenovirus-vector 
(Ad-vector) during the third week. Serum IL-22 levels 
were undetectable in the Ad-vector-treated mice but 
had  risen  to  high  levels  (10  ng/ml)  after  Ad-IL-22 
administration (Fig. 4A). Chronic cerulein treatment 
elevated serum amylase and lipase levels, which were 
markedly  reduced  by  Ad-IL-22  treatment  (Fig.  4A). 
H&E  and  MPO  staining  indicated  that  Ad-IL-22 
treatment  also  markedly  ameliorated  chronic  ceru-
lein-induced  pancreatic  damage  and  MPO+  neutro-
phil  infiltration  compared  to  the  Ad-vector-treated 






Figure 3. Treatment with recombinant 
murine  IL-22  (rmIL-22)  protein  ame-
liorates  cerulein-induced  acute  pan-
creatitis in mice. Recombinant IL-22 pro-
tein was administrated to C57BL/6 mice two 
hours before the first of seven hourly ceru-
lein. Mice were sacrificed one hour after the 
last cerulein injection. The ratio of pancreas 
weight to body weight and serum levels of 
amylase  and  lipase  were  measured  (A). 
Representative examples of H&E and MPO 
staining are shown in the left panel of (B), and 
the pathology score and the number of MPO+ 
cells are summarized in the right panel of (B). 
**P<0.05, **P < 0.01, and ***P<0.001. Data 
are representative of three different exper-

















Figure  4.  Treatment  with 
adeno-IL-22  ameliorates  chronic 
cerulein-induced  pancreatitis  in 
mice.  C57BL6  mice  received  a  set  of 
seven injections of cerulein weekly for four 
weeks.  Ad-vector  or  Ad-IL-22  was  in-
jected on the 3rd week. Mice were sacri-
ficed one hour after the last cerulein in-
jection. Serum levels of IL-22, amylase and 
lipase levels were measured (A). Repre-
sentative  H&E  and  MPO  staining  are 
shown  in  the  left  panel  of  (B).  The  pa-
thology scores and the number of MPO+ 
cells are summarized in the right panel of 
(B). ** P < 0.01, *** P < 0.001. Data are 
representative  of  three  different  experi-
ments, 3~5 mice in each group. 
 
 




In summary, the above data clearly indicate that 
IL-22  treatment  ameliorates  cerulein-induced  acute 
and chronic pancreatitis.  
The protective role of IL-22 in pancreatitis is 
mediated by the induction of Bcl-2 and Bcl-XL, 
which bind to beclin-1 and subsequently inhibit 
autophagy  
Although the mechanisms underlying pancrea-
titis are not fully understood, accumulating evidence 
has  suggested  that  autophagosome  formation  and 
impaired autophagic flux due to deficient lysosomal 
degradation are important mechanisms contributing 
to  the  pathogenesis  of  pancreatitis  [19,  21-23].  The 
accumulation  of  large  vacuoles  in  acinar  cells  is  a 
prominent observation in human pancreatitis samples 
and in various rodent models of pancreatitis [19]. The 
deletion  of  ATG5,  an  important  component  for  au-
tophagosome  formation,  prevents  cerulein-induced 
acute pancreatitis, suggesting that excessive autoph-
agy leads to intra-acinar trypsinogen activation [24]. 
In agreement with previous findings, immunohisto-
chemical and electronic microscopic analyses indicate 
that repeated cerulein injection results in acute pan-
creatitis with accumulation of LC-3 staining and large 
autophagosomes in WT mice (Figs. 5A-B). In contrast, 
the number and size of autophagosomes are markedly 
reduced in IL-22TG mice (Figs. 5A-B). Interestingly, 
acinar cells from cerulein-treated IL-22TG mice often 
exhibited numerous  multilamellar structures closely 
associated  with  or  opposed  to  mitochondria  which 
have been described as an early event in formation of 
autopagosomes [25]. An abundance of such structures 
along  with  the  scarcity  of  their  later,  more  mature 
stages and the lack of large autopagosome suggests 
that IL-22 might affect membrane biogenesis in au-
tophagy, thereby blocking cerulein-induced autoph-
agosome formation (b2 and b3 in Fig. 5B). 
Little is known about how repeated cerulein in-
jections  induce  autophagosome  formation,  although 
several factors, such as VMP1, USP9x, and Beclin-1, 
have  been  implicated  [26-28].  Beclin-1  has  been  re-
ported to either stimulate autophagy (autophagosome 
formation) by interacting with hVps34 or inhibit it by 
interacting with Bcl-2, Bcl-XL, and Mcl-1 [29-31]. To 
explore the underlying  mechanisms by  which ceru-
lein-induced autophagosome formation was inhibited 
in  IL-22TG  mice,  we  analyzed  these  authopha-
gy-related  proteins  by  Western  blot  analyses.  As 
shown  in  Figure  6A,  the  expression  levels  of  the 
pSTAT3,  STAT3,  Bcl-2,  and  Bcl-XL  proteins  were 
much  higher  in  the  pancreases  from  IL-22TG  mice 
compared  to  WT  mice.  In  contrast,  the  expression 
levels of the Mcl-1, VMP1, and USP9x proteins in the 
pancreas were similar between these two groups. 
Moreover, immunoprecipitation assays showed 
that higher levels of Bcl-1 or Bcl-XL bind Beclin-1 in 
the pancreases from IL-22TG mice compared to WT 
mice (Fig. 6B), which is likely due to upregulated ex-
pression of Bcl-2 and Bcl-XL proteins in the IL-22TG 
mice. These findings suggest that IL-22 upregulates 
the expression of Bcl-2 and Bcl-XL and subsequently 
enhances the interaction of Bcl-2 or Bcl-XL with Be-
clin-1, thereby inhibiting autophagy (autophagosome 
formation) and pancreatitis.  
Discussion 
In this study, we showed that IL-22 effectively 
protected mice from cerulein induced acute or chronic 
pancreatitis. This is likely mediated via the induction 
of Bcl-2 and Bcl-XL gene expression in pancreas and 
subsequent reduction of autophagosome formation, a 
critical  step  in  the  initialization  of  pancreatitis  [19, 
21-23]. 
Accumulating evidence suggests that autophagy 
in acinar cells is a critical process in the pathogenesis 
of  pancreatitis.  Autophagy  comprises  two  key  se-
quential steps: first the formation of autophagosomes 
that  sequester  the  organelles  destined  for  degrada-
tion; and second the fusion of autophagosomes with 
lysosomes to form autolysosomes where materials are 
degraded by hydrolases including the cathepsin fam-
ily of proteases. Recent studies have suggested that 
impaired autophagic influx due to deficient lysosomal 
degradation is an important mechanism that contrib-
utes to intra-acinar trypsin activation and pancreatitis 
[19, 21, 23]. In addition, mice deficient in the ability to 
form autophagosomes are resistant to acute pancrea-
titis  [24],  suggesting  that  formation  of  autophago-
somes is also an important step to develop pancreati-
tis. In our study, we found that cerulein-induced au-
tophagosime formation was markedly diminished in 
IL-22TG mice compared with WT mice (Figs. 5A-B), 
indicating that the protective effect of IL-22 on ceru-
lein-induced  pancreatitis  is  mediated  by  inhibiting 
autophagosome formation.  
Next we asked how IL-22 inhibits autophagy in 
cerulein-induced  pancreatitis.  To  date,  three  major 
pathways that regulate autophagy have been identi-
fied. These include the inhibitory mammalian target 
of rapamycin (mTOR) pathway, the stimulatory be-
clin-1 (also called ATG6) pathway, and the stimula-
tory LC3-II/Atg5-Atg12-Atg16 pathway [22]. Recent 
studies have suggested that Bcl-2 and Bcl-XL play an 
important role in inhibiting the stimulatory beclin-1 
pathway  by  binding  to  beclin-1  and  subsequently 






Figure 5. Reduced autophagosome formation in the pancreases of cerulein-treated IL-22TG mice. WT and IL-22TG mice 
received seven cerulein or PBS injections and were sacrificed one hour after the last injection. Pancreases were collected for immuno-
histochemical or electron microscopy analyses. (A) Representative immunohistochemical staining with anti-LC3 antibody. Arrows indi-
cate the LC3-postive vesicles. (B) Electron micrographs of pancreatic tissues from WT (a1, a2, a3, a4) and IL-22TG (b1, b2, b3) mice treated 
with cerulein. (a1 and a2) Acinar cells from cerulein-treated WT mice contain one large and many small autophagosomes at different stages 
of maturation (long arrows). (a3 and a4) higher magnification of autophagosomes containing mitochondria (M) and other intracellular 
organelles such as zymogen (ZG). Please note the double membrane (insert in a1) surrounding autophagosomes. (b1) In contrast to WT, 
acinar cells from cerlulein-treated IL-22TG mice display only a few small autophagosomes (long arrow). (b2 and b3) mutilammellar 





Figure 6. Upregulation of Bcl-2 and Bcl-XL, which bind Beclin-1, was associated reduced autophagosome formation in 
the pancreases of cerulein-treated IL-22TG mice. (A) Western blot analyses of pancreatic protein extracts from WT and IL-22TG 
mice. (B) Immunoprecipitation analyses of the interaction of Beclin-1 with Bcl-2 family proteins. (C) Scheme of the mechanisms underlying 
IL-22 inhibition of autophagy and pancreatitis. Data are representative of three different experiments. 
 
 
Several previous studies have demonstrated that 
STAT3 activation induces the expression of Bcl-2 and 
Bcl-XL  in  a  variety  of  cell  types  via  transcriptional 
upregulation of these genes [32]. Thus, we speculated 
that upregulated Bcl-2 and Bcl-XL in the pancreases of 
IL-22TG  mice  are  likely  due  to  the  enhanced  IL-22 
activation of STAT3. This hypothesis was supported 
by our experimental data that expression of pSTAT3, 
Bcl-2 and Bcl-XL levels was much higher in the pan-
creas of IL-22TG mice than that in WT mice (Fig. 6A). 
Moreover,  immunoprecipitation  assays  in  Fig.  6B 
showed that binding of Bcl-2 or Bcl-XL with Beclin 1 
was  enhanced  in  the  pancreas  from  IL-22TG  mice 
compared  with  WT  mice.  Collectively,  our  findings 
suggest that IL-22 activates STAT3 and then upregu-
lates the STAT3 downstream genes such as Bcl-2 and 
Bcl-XL. Increased Bcl-2 and Bcl-XL subsequently binds 
to  Beclin1  and  inhibits  autophagosome  formation, 
thereby  ameliorating  acinar  cell  damage  in  ceru-
lein-induced pancreatitis (Fig. 6C). 
Chronic alcohol drinking is a leading cause for 
both acute and chronic pancreatitis  [1-3]. Thus, fur-
ther studies of the protective effects of IL-22 on alco-
holic  pancreatitis  are  urgently  needed.  Alcoholic 
pancreatitis is attributed to its non-oxidative metabo-
lism  by  phospholipase  D  (PLD)  to  fatty  acid  ethyl 
esters (FAEEs) generated in the pancreatic acinar cells 
[33, 34]. It will be interesting to determine whether 
IL-22 affects the interaction between PLD activation 
and  formation  of  FAEEs  (or  phosphatidylethanol), 
thereby  ameliorating  alcoholic  pancreatitis.  In  addi-
tion, rats fed ethanol diet for 14 weeks, then received a 
single lipopolysaccharide injection showed depletion 
of  several  lysosomal  proteins  including  lysoso-
mal-associated membrane protein-2 (Lamp-2), an es-
sential lysosomal membrane protein that is required 
for the proper fusion of autophagosomes with lyso-
somes [35]. Accordingly, Lamp-2 depletion is report-
ed to inhibit the fusion of lysosomes and autophago-
somes, thus causing the accumulation of autophago-
somes  [36,  37].  Importantly,  patients  with  alcoholic 
pancreatitis  also  exhibit  local  Lamp-2  depletion, 
which highlights the important role of Lamp-2 in in-
hibiting autophagy and  pancreatic acinar cell death 
[35]. It will be important  to examine whether IL-22 
regulates Lamp-2 gene expression and subsequently 
ameliorates alcoholic pancreatitis. 
In  summary,  IL-22  treatment  appears  to  have 
beneficial  effects  on  acute  and  chronic  pancreatitis 
with the added benefit of potentially few side effects 
due to the restricted expression of IL-22R [38]. Clinical 
trials examining IL-22 treatment for pancreatitis are 
therefore a reasonable next step.  
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